Dihydromyricetin: A potential candidate for the treatment of cholestatic liver injury via inhibition of the NLRP3 inflammasome
Hao ZhangThe Second School of Clinical Medicine of Binzhou Medical University, Yantai, 264003, China; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaYiping DangDepartment of Vascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaYuanjin GuoDepartment of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, ChinaDavid FisherDepartment of Medical Biosciences, Faculty of Natural Sciences, University of The Western Cape, Cape Town, South AfricaNguyen Thi Thu HienHai Phong University of Medicine and Pharmacy, Hai Phong, 04212, Viet NamErkin MusabaevThe Research Institute of Virology, Ministry of Health, Tashkent, 100122, UzbekistanVadim V. ShmanaiInstitute of Physical Organic Chemistry, National Academy of Sciences of Belarus, Surganova 13, Minsk, 220072, Belarus朱智德The First Clinical Medical College, Guangxi University of Chinese Medicine, Nanning, 530023, China. Electronic address: [email protected]Miao LuoDepartment of Infectious Diseases, Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Zhengzhou, China. Electronic address: [email protected]Chunxia GeThe Second School of Clinical Medicine of Binzhou Medical University, Yantai, 264003, China. Electronic address: [email protected]Lei ZhaoThe Second School of Clinical Medicine of Binzhou Medical University, Yantai, 264003, China; Department of Infectious Diseases, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China. Electronic address: [email protected]
ABI
Аннотация
Аннотация мавжуд эмас.
Мавзулар
Идентификаторлар
Иқтибослар ва манбалар
0 та иқтибос56 та фойдаланилган манба